Skip to main content

PainReform Ltd. (PRFX)

NASDAQ: PRFX · IEX Real-Time Price · USD
2.50 -0.16 (-6.02%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap27.88M
Revenue (ttm)n/a
Net Income (ttm)-5.83M
Shares Out10.07M
EPS (ttm)-0.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,131
Open2.62
Previous Close2.66
Day's Range2.48 - 2.67
52-Week Range2.18 - 7.84
Betan/a
AnalystsBuy
Price Target6.00 (+140.0%)
Est. Earnings DateNov 10, 2021

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporat...

IndustryDrug Manufacturers-Specialty & Generic
IPO DateSep 1, 2020
Employees1
Stock ExchangeNASDAQ
Ticker SymbolPRFX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for PainReform stock is "Buy" and the 12-month stock price forecast is 6.00.

Price Target
$6.00
(140.00% upside)
Analyst Consensus: Buy

News

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

TEL AVIV, Israel, Oct. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of esta...

1 week ago - GlobeNewsWire

PainReform Provides Business Update for the Second Quarter of 2021

Shifting manufacturing and scale up operation to U.S.-based Contract Development and Manufacturing Organization for PRF-110 Shifting manufacturing and scale up operation to U.S.-based Contract Developme...

2 months ago - GlobeNewsWire

Highest Volume Penny Stocks to Watch Today? Check These 4 Out

Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?

Other symbols:EYESIGC
2 months ago - PennyStocks

PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading

We're seeing lots of activity from penny stock PainReform (PRFX) on Wednesday despite a lack of news from the pharmaceutical company. The post PRFX Stock: 7 Things to Know About Pharmaceutical Company P...

Other symbols:NUROSOS
3 months ago - InvestorPlace

PainReform Provides Business Update for the First Quarter of 2021

Reports continued progress towards start of Phase 3 trials Reports continued progress towards start of Phase 3 trials

5 months ago - GlobeNewsWire

PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non...

HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

7 months ago - GlobeNewsWire

PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

HERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

7 months ago - GlobeNewsWire

PainReform Announces $6.0 Million Private Placement

HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of est...

7 months ago - GlobeNewsWire

PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of esta...

9 months ago - GlobeNewsWire

PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of esta...

9 months ago - GlobeNewsWire